Celyad Oncology Sa (CYAD) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access CYAD Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Celyad Oncology Sa generates earnings and manages operating expenses.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2022)
Q4 2022
0 0 0 (Dec 31 2021)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing11.81
Research and Development Expense21.20
Other Operating Expense / -Income12.75
Total operating costs including COS45.76
Operating income / -loss-45.76
Net Interest (-)Expense / Income0.00
Other loss / -income-0.38
Total costs & expenses45.77
Income & Taxes
Income / -loss before income taxes-45.77
Income taxes expenses / -benefit0.07
Income after income taxes-45.85
Income / -loss from continuing operations-45.85
Net income / -loss-45.85
Income / -loss to shareholder-45.85
EBIT-45.77
EBITD-44.85
EBITDA-44.16
Earnings Per Share
Basic EPS (excl. extra items)-2.03
Basic Net EPS-2.03
Basic shares outstanding (Mill. of Units)22.59
Diluted Net EPS-2.03
Diluted average shares (Mill. of Units)22.59
4 historic quarters locked

Sign in to unlock the full Celyad Oncology Sa income statement history.

About CYAD Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.